[go: up one dir, main page]

RU96111557A - METHOD FOR TREATING NEUROSENSOR Hearing Aid - Google Patents

METHOD FOR TREATING NEUROSENSOR Hearing Aid

Info

Publication number
RU96111557A
RU96111557A RU96111557/14A RU96111557A RU96111557A RU 96111557 A RU96111557 A RU 96111557A RU 96111557/14 A RU96111557/14 A RU 96111557/14A RU 96111557 A RU96111557 A RU 96111557A RU 96111557 A RU96111557 A RU 96111557A
Authority
RU
Russia
Prior art keywords
treating
neurosensor
hearing aid
ceruloplasmin
molecular weight
Prior art date
Application number
RU96111557/14A
Other languages
Russian (ru)
Other versions
RU2108793C1 (en
Inventor
Н.В. Атаманова
И.Г. Самойлова
Original Assignee
Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи МЗМП РФ
Н.В. Атаманова
Filing date
Publication date
Application filed by Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи МЗМП РФ, Н.В. Атаманова filed Critical Санкт-Петербургский научно-исследовательский институт уха, горла, носа и речи МЗМП РФ
Priority to RU96111557A priority Critical patent/RU2108793C1/en
Priority claimed from RU96111557A external-priority patent/RU2108793C1/en
Application granted granted Critical
Publication of RU2108793C1 publication Critical patent/RU2108793C1/en
Publication of RU96111557A publication Critical patent/RU96111557A/en

Links

Claims (1)

Способ лечения нейросенсорной тугоухости посредством белкового препарата, отличающийся тем, что предварительно проводят биохимическое исследование крови на содержание в ней церулоплазмина и веществ с молекулярной массой 300 - 5000 Д, а в качестве белкового препарата используют человеческий церулоплазмин, который вводят при содержании веществ с молекулярной массой 300 - 5000 Д более 0,250 ед. и церулоплазмина - не более 65 мг%, причем вводят его внутривенно капельно в количестве 1,5 мг/кг ежедневно в те6чение 5 - 7 дней.A method of treating sensorineural hearing loss with a protein preparation, characterized in that a biochemical blood test is carried out previously for the content of ceruloplasmin and substances with a molecular weight of 300-5000 D in it, and human ceruloplasmin is used as a protein preparation, which is administered when containing substances with a molecular weight of 300 - 5000 D more than 0.250 units. and ceruloplasmin - not more than 65 mg%, moreover, it is administered intravenously in an amount of 1.5 mg / kg daily for 6-7 days.
RU96111557A 1996-06-20 1996-06-20 Method of treatment of neurosensory impaired hearing RU2108793C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU96111557A RU2108793C1 (en) 1996-06-20 1996-06-20 Method of treatment of neurosensory impaired hearing

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU96111557A RU2108793C1 (en) 1996-06-20 1996-06-20 Method of treatment of neurosensory impaired hearing

Publications (2)

Publication Number Publication Date
RU2108793C1 RU2108793C1 (en) 1998-04-20
RU96111557A true RU96111557A (en) 1998-08-27

Family

ID=20181691

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96111557A RU2108793C1 (en) 1996-06-20 1996-06-20 Method of treatment of neurosensory impaired hearing

Country Status (1)

Country Link
RU (1) RU2108793C1 (en)

Similar Documents

Publication Publication Date Title
EP2270046A3 (en) Methods and compositions for the treatment of hemolysis-associated diseases
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
EA199800946A1 (en) CONCENTRATED ANTIBODY PREPARATION
EP1449921A3 (en) Novel biologically active polypeptides, preparation thereof and pharmaceutical composition containing said polypeptides
DE69710095D1 (en) PHARMACEUTICAL PREPARATION FOR TREATING DIABETES
DE69027865D1 (en) COMPOSITIONS containing omega conotoxin peptide derivatives and their use for the treatment of ischemic-like neuronal damage
FR2707882B1 (en) New protein anti-mediator therapeutic kits, preparation process and pharmaceutical compositions containing them.
EP0570916A3 (en) Human recombinant serum albumin, process for its preparation and pharmaceutical preparations containing it.
DE59509848D1 (en) COMBINATION PRODUCT FOR USE IN IMMUNOLOGICAL DISEASES
CA2294921A1 (en) Levobupivacaine and its use
EE200000054A (en) Pharmaceutical composition containing vitamin D and calcium, its preparation and therapeutic use
NZ230155A (en) N-2,3-butadienyl-n"-substituted-triamindalkanes and alkenes, and pharmaceutical compositions
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
ATE100095T1 (en) 2,2-DIMETHYLCHROMONE DERIVATIVES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP0744176A3 (en) Methods for inhibiting bone loss
IT1241631B (en) "N, N'-DITRIMETOSSIBENZOILPIPERAZINE 2-REPLACED, PROCEDURE FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS CONTAINING THEM
DE69201351D1 (en) Whey protein gel and process for its preparation.
RU96111557A (en) METHOD FOR TREATING NEUROSENSOR Hearing Aid
RU96118931A (en) MEANS FOR INFLUENCE ON THE ORGANISM
ITTO950554A0 (en) ACID AROMATIC DIAMIDES WITH ANTIGASTRINIC ACTIVITY, PROCEDURE FOR THEIR PREPARATION AND PHARMACEUTICAL USE
FR2702211B1 (en) New derivatives of 2-phenoxyethylamine, their preparation and their therapeutic use.
AU6826487A (en) Surgery for strengthening tendon in horses leg
EA199900006A1 (en) PREPARATION AND METHOD FOR THE TREATMENT OF STRONG HEART FAILURE
AU1939697A (en) Physiologically active substances tkr1785's, process for the preparation thereof, and microbe
AUPN115095A0 (en) Analysis of and compositions and methods for the treatment of disease